Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lubiprostone 24 Clear all
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

NCT00844831
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

NCT00597428
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
109
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tempe, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis

NCT00706004
View directory record Official record
Conditions
Constipation, Cystic Fibrosis
Interventions
lubiprostone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

NCT00662363
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone, Senna
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intestinal Microecology in Chronic Constipation

NCT00934479
View directory record Official record
Conditions
Other Constipation, Irritable Bowel Syndrome
Interventions
Lubiprostone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

NCT01162863
View directory record Official record
Conditions
Irritable Bowel Syndrome, Constipation
Interventions
Lubiprostone, Placebo, Smartpill wireless motility capsule
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 1 Interventional Results available

Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.

NCT01190020
View directory record Official record
Conditions
Chronic Constipation, Methanogenesis
Interventions
Lubiprostone, Lubiprostone Control
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Lubiprostone for Children With Constipation

NCT02138136
View directory record Official record
Conditions
Constipation - Functional
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
67
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lubiprostone, Colonic Motility and Sensation

NCT00953043
View directory record Official record
Conditions
Healthy
Interventions
lubiprostone, Placebo, Bowel preparation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 8, 2026, 5:41 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation

NCT04361656
View directory record Official record
Conditions
Colonoscopy Preparation
Interventions
PEG-ELS current standard of care, PEG-ELS current standard of care plus Lubiprostone 24 microgram Oral Cap (x2)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation

NCT01236534
View directory record Official record
Conditions
Multiple Sclerosis, Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

NCT01839734
View directory record Official record
Conditions
HIV
Interventions
Lubiprostone
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 8, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Results available

Lubiprostone as a Treatment for Constipation in Parkinson's Disease

NCT00669461
View directory record Official record
Conditions
Constipation, Parkinson's Disease
Interventions
Lubiprostone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
50 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

NCT00452335
View directory record Official record
Conditions
Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
lubiprostone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

NCT01469819
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

NCT02766777
View directory record Official record
Conditions
Constipation - Functional
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Fayetteville, Arkansas • Peoria, Illinois • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation

NCT00645801
View directory record Official record
Conditions
Colonoscopy
Interventions
lubiprostone (Amitiza), Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • Novi, Michigan • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 8, 2026, 5:41 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of Lubiprostone in Combination With Standard PEG Preparation

NCT00689026
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Lubiprostone, Polyethylene glycol with electrolytes
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

NCT00746395
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 8, 2026, 5:41 AM EDT
Completed Phase 3 Interventional

Evaluation of Clinical Equivalence Between Two Lubiprostone Products

NCT01372423
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Anchen Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
79
States / cities
Dothan, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Sep 8, 2026, 5:41 AM EDT